The preclinical trial, led by Professor Maziar Divangahi, uncovered that beta-glucan, also present in yeast, can “reprogramme” immune cells to prevent lung inflammation.
His team demonstrated that administering the compound to mice before their exposure to influenza, reduced lung damage, improved lung function, and lowered the risk of illness and death.